Difference between revisions of "Dexrazoxane (Zinecard)"
m |
m |
||
| Line 18: | Line 18: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chelators]] | [[Category:Chelators]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1995]] | ||
Revision as of 14:18, 1 November 2014
General information
Class/mechanism: Intracellular chelating agent derived from EDTA. Mechanism not fully understood, but hypothesized to protect against anthracycline-caused cardiomyopathy by interfering with iron-mediated free radical generation. Also used in cases of anthracycline extravasation.[1][2][3][4][5]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Dexrazoxane (Zinecard) patient drug information (Chemocare)[6]
- Dexrazoxane (Zinecard) patient drug information (UpToDate)[7]
Also known as
Cardioxane, Dexrazoxane hydrochloride, or Totect.
References
- ↑ 1.0 1.1 Dexrazoxane (Zinecard) package insert
- ↑ Dexrazoxane (Zinecard) package insert (locally hosted backup)
- ↑ Zinecard manufacturer's website
- ↑ Dexrazoxane (Totect) package insert
- ↑ Totect manufacturer's website
- ↑ Dexrazoxane (Zinecard) patient drug information (Chemocare)
- ↑ Dexrazoxane (Zinecard) patient drug information (UpToDate)